No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
IE
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
VAC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
doxorubicin hydrochloride + cyclophosphamide oral + etoposide IV + vincristine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
trabectedin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
ADX-2191
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
topotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
SA033
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
cyclophosphamide oral + vinorelbine tartrate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
carboplatin + etoposide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
vincristine + dactinomycin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
irinotecan + vincristine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
ifosfamide + doxorubicin hydrochloride
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
cyclophosphamide oral + topotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
ifosfamide + doxorubicin hydrochloride + vincristine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
ifosfamide + doxorubicin hydrochloride + cyclophosphamide oral + vincristine
Sensitive: A2 - Guideline
|
BRAF-MAD1L1 fusion
BRAF-MAD1L1 fusion
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
anlotinib
Resistant: C4 – Case Studies
|
HRAS mutation
HRAS mutation
|
Rhabdomyosarcoma
Rhabdomyosarcoma
|
tipifarnib
Sensitive: D – Preclinical
|
